Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Rectal Cancer Treatment Response Using PET/MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of histopathologically confirmed rectal adenocarcinoma.~* Locally advanced disease as determined by ERUS or pelvic MRI. Endoscopy reports should clearly state both the T and N stage.~* Patients with cT2N1-3M0 or cT2-4NxM0 will be considered eligible for participation.~* Age ≥18.~* Ability to understand a written informed consent document and the willingness to sign it.~* Tumor must be determined to be surgically resectable. Surgical resection is planned to take place at Univeristy of California, San Francisco (UCSF).~* Neoadjuvant chemoradiation prior to resection is planned..~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.~Exclusion Criteria:~* ERUS tumor state of T1.~* Radiographic evidence of metastatic disease~* Weight in excess of limitations of the scanner or girth that prohibits entry into the bore of the PET/CT scanner due to size.~* Any medical condition which impairs the ability to lie flat and without movement for 15 minutes (e.g. cough, severe arthritis, etc.)~* Prior receipt of any therapy, including local excision, radiation or chemotherapy, for the diagnosed rectal adenocarcinoma.~* Prior history of pelvic radiation.~* Uncontrolled hyperglycemia (defined as inability to achieve a glucose of \<250 mg/dL at time of fluorodeoxyglucose (FDG) injection).~* Impaired renal function (CKD 4 or 5: estimated glomerular filtration rate (eGFR) \< 30 mLs/min), which is a contraindication to gadolinium containing contrast.~* Known allergy to gadolinium containing contrast agents.~* Contraindication to use of fluoropyrimidines as a radiosensitizing agent.~* Pregnancy or nursing. Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to randomization. This is because of the potential teratogenic effects of the involved imaging modalities, radiation, and chemotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adjuvant chemotherapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).